晚期肝细胞癌系统治疗的研究进展

李世思; 郭志唐; 陈章彬; 滕毅山

doi:10.3969/j.issn.1001-5256.2021.12.044

晚期肝细胞癌系统治疗的研究进展

DOI: 10.3969/j.issn.1001-5256.2021.12.044

昆明医科大学第二附属医院肝胆胰外科三病区，昆明 650101

详细信息

通信作者:
滕毅山，teng_yishan@163.com

中图分类号: R735.7
计量
- 文章访问数: 408
- HTML全文浏览量: 207
- PDF下载量: 56
- 被引次数: 0
出版历程
- 收稿日期: 2021-05-25
- 录用日期: 2021-07-20
- 出版日期: 2021-12-20

Research advances in systemic therapy for advanced hepatocellular carcinoma

The Third Ward of Hepatobiliary and Pancreatic Surgery, The Second Affiliated Hospital of Kunming Medical University, Kunming 650101, China

摘要

摘要: 肝细胞癌(HCC)是一种常见且预后较差的恶性肿瘤，手术切除是治疗HCC的首选方法，但对晚期HCC的治疗效果有限，而系统治疗在晚期不可切除HCC治疗中发挥重要作用。归纳了近年国内外关于不可切除性肝癌系统治疗的相关进展，包括多种酪氨酸激酶抑制剂，如索拉非尼、仑伐替尼、瑞戈非尼和卡博替尼，以及阿替唑珠单抗、帕博利珠单抗、纳武单抗等免疫检查点抑制剂。分析表明，对于不可切除的HCC患者，系统治疗能一定程度上延长患者的生存时间，而联合治疗方案现已成为新的研究热点，未来将进一步探索个体化系统治疗策略。
- 癌, 肝细胞 /
- 药物疗法 /
- 免疫疗法
Abstract: Hepatocellular carcinoma (HCC) is a common malignant tumor with poor prognosis, and surgical resection is the preferred method for the treatment of HCC, but it has a limited therapeutic effect on advanced HCC, while systemic treatment plays an important role in the treatment of advanced unresectable HCC. This article summarizes the advances in systemic therapy for unresectable liver cancer in China and globally in recent years, including a variety of tyrosine kinase inhibitors (sorafenib, lenvatinib, regorafenib, and cabozantinib) and immune checkpoint inhibitors (atezolizumab, pembrolizumab, and nivolumab). The analysis shows that for patients with unresectable HCC, systemic therapy can prolong the survival time of patients to a certain extent, and combined treatment regimen has become a new research hotspot. Individualized systemic treatment strategies will be further explored in the future.
- Carcinoma, Hepatocellular /
- Drug Therapy /
- Immunotherapy

HTML全文

参考文献(36)

[1]	BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. DOI: 10.3322/caac.21492.
[2]	SIEGEL RL, MILLER KD, JEMAL A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1): 7-30. DOI: 10.3322/caac.21590.
[3]	Bureau of Medical Administration National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007. 中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
[4]	LLOVET JM, RICCI S, MAZZAFERRO V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI: 10.1056/NEJMoa0708857.
[5]	CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7.
[6]	BRUIX J, RAOUL JL, SHERMAN M, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: subanalyses of a phase Ⅲ trial[J]. J Hepatol, 2012, 57(4): 821-829. DOI: 10.1016/j.jhep.2012.06.014.
[7]	VOGEL A, SABOROWSKI A. Current strategies for the treatment of intermediate and advanced hepatocellular carcinoma[J]. Cancer Treat Rev, 2020, 82: 101946. DOI: 10.1016/j.ctrv.2019.101946.
[8]	BRUIX J, CHENG AL, MEINHARDT G, et al. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase Ⅲ studies[J]. J Hepatol, 2017, 67(5): 999-1008. DOI: 10.1016/j.jhep.2017.06.026.
[9]	BERHANE S, FOX R, GARCÍA-FIÑANA M, et al. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment[J]. Br J Cancer, 2019, 121(2): 117-124. DOI: 10.1038/s41416-019-0488-4.
[10]	KUDO M, FINN RS, QIN S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173. DOI: 10.1016/S0140-6736(18)30207-1.
[11]	KUDO M, UESHIMA K, CHAN S, et al. Lenvatinib as an initial treatment in patients with intermediate-stage hepatocellular carcinoma beyond Up-To-seven criteria and Child-Pugh a liver function: A proof-of-concept study[J]. Cancers (Basel), 2019, 11(8): 1084. DOI: 10.3390/cancers11081084.
[12]	SHO T, SUDA G, OGAWA K, et al. Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria[J]. Hepatol Res, 2020, 50(8): 966-977. DOI: 10.1111/hepr.13511.
[13]	VOGEL A, FRENETTE C, SUNG MW, et al. Baseline liver function and outcomes in the phase Ⅲ REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC)[J]. J Clin Oncol, 2020, 38(suppl 4): 524. DOI: 10.1200/JCO.2020.38.4_suppl.524.
[14]	HATANAKA T, KAKIZAKI S, NAGASHIMA T, et al. Analyses of objective response rate, progression-free survival, and adverse events in hepatocellular carcinoma patients treated with lenvatinib: A multicenter retrospective study[J]. Hepatol Res, 2020, 50(3): 382-395. DOI: 10.1111/hepr.13460.
[15]	MARUTA S, OGASAWARA S, OOKA Y, et al. Potential of lenvatinib for an expanded indication from the REFLECT trial in patients with advanced hepatocellular carcinoma[J]. Liver Cancer, 2020, 9(4): 382-396. DOI: 10.1159/000507022.
[16]	BI F, QIN S, GU S, et al. Donafenib versus sorafenib as first-line therapy in advanced hepatocellular carcinoma: An open-label, randomized, multicenter phase Ⅱ/Ⅲ trial[J]. J Clin Oncol, 2020, 38(15): 4506-4506. DOI: 10.1200/JCO.21.00163.
[17]	LEE MS, RYOO BY, HSU CH, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study[J]. Lancet Oncol, 2020, 21(6): 808-820. DOI: 10.1016/S1470-2045(20)30156-X.
[18]	FINN RS, QIN S, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905. DOI: 10.1056/NEJMoa1915745.
[19]	GALLE PR, FINN RS, QIN S, et al. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): An open-label, randomised, phase 3 trial[J]. Lancet Oncol, 2021, 22(7): 991-1001. DOI: 10.1016/S1470-2045(21)00151-0.
[20]	BRUIX J, QIN S, MERLE P, et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2017, 389(10064): 56-66. DOI: 10.1016/S0140-6736(16)32453-9.
[21]	FINN RS, MERLE P, GRANITO A, et al. Outcomes of sequential treatment with sorafenib followed by regorafenib for HCC: Additional analyses from the phase Ⅲ RESORCE trial[J]. J Hepatol, 2018, 69(2): 353-358. DOI: 10.1016/j.jhep.2018.04.010.
[22]	ABOU-ALFA GK, MEYER T, CHENG AL, et al. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma[J]. N Engl J Med, 2018, 379(1): 54-63. DOI: 10.1056/NEJMoa1717002.
[23]	KELLEY RK, RYOO BY, MERLE P, et al. Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: A subgroup analysis of the phase 3 CELESTIAL trial[J]. ESMO Open, 2020, 5(4). DOI: 10.1136/esmoopen-2020-000714.
[24]	RIMASSA L, WÖRNS MA. Navigating the new landscape of second-line treatment in advanced hepatocellular carcinoma[J]. Liver Int, 2020, 40(8): 1800-1811. DOI: 10.1111/liv.14533.
[25]	DEBAILLON VESQUE A, DECRAECKER M, BLANC JF. Profile of cabozantinib for the treatment of hepatocellular carcinoma: Patient selection and special considerations[J]. J Hepatocell Carcinoma, 2020, 7: 91-99. DOI: 10.2147/JHC.S195570.
[26]	KELLEY RK, W OLIVER J, HAZRA S, et al. Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase Ⅲ study design[J]. Future Oncol, 2020, 16(21): 1525-1536. DOI: 10.2217/fon-2020-0283.
[27]	ZHU AX, PARK JO, RYOO BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): A randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2015, 16(7): 859-870. DOI: 10.1016/S1470-2045(15)00050-9.
[28]	ZHU AX, KANG YK, YEN CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296. DOI: 10.1016/S1470-2045(18)30937-9.
[29]	KUZUYA T, ISHIGAMI M, ITO T, et al. Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma[J]. Anticancer Res, 2020, 40(4): 2089-2093. DOI: 10.21873/anticanres.14167.
[30]	ZHU AX, NIPP RD, FINN RS, et al. Ramucirumab in the second-line for patients with hepatocellular carcinoma and elevated alpha-fetoprotein: Patient-reported outcomes across two randomised clinical trials[J]. ESMO Open, 2020, 5(4): e000797. DOI: 10.1136/esmoopen-2020-000797.
[31]	ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6.
[32]	FINN RS, RYOO BY, MERLE P, et al. Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase Ⅲ trial[J]. J Clin Oncol, 2020, 38(3): 193-202. DOI: 10.1200/JCO.19.01307.
[33]	FINN RS, IKEDA M, ZHU AX, et al. Phase Ib study of lenvatinib plus pembrolizumab in patients with unresectable hepatocellular carcinoma[J]. J Clin Oncol, 2020, 38(26): 2960-2970. DOI: 10.1200/JCO.20.00808.
[34]	EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2.
[35]	YAU T, PARK JW, FINN RS, et al. CheckMate 459: A randomized, multi-center phase Ⅲ study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)[J]. Ann Oncol, 2019, 30. DOI: 10.1093/annonc/mdz394.029
[36]	YAU T, KANG YK, KIM TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: The checkmate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564. DOI: 10.1001/jamaoncol.2020.4564.